Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Sponsor: Bristol-Myers Squibb
Summary
This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.
Official title: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
336
Start Date
2022-06-09
Completion Date
2027-12-10
Last Updated
2025-12-05
Healthy Volunteers
No
Conditions
Interventions
MRTX1719
MRTX1719 is a potent PRMT5-MTA inhibitor. Specified dose on specified days
Locations (25)
Mayo Clinic
Phoenix, Arizona, United States
Sarah Cannon Research Institute (SCRI) - HealthONE Location
Denver, Colorado, United States
Rocky Mountain Cancer Centers, LLP - Oncology
Lone Tree, Colorado, United States
Mayo Clinic
Jacksonville, Florida, United States
Sarah Cannon Research Institute at Florida Cancer Specialists
Orlando, Florida, United States
Local Institution - 124
Chicago, Illinois, United States
Dana-Farber Cancer Institute
Brookline, Massachusetts, United States
Cancer and Hematology Centers of Western Michigan
Norton Shores, Michigan, United States
Mayo Clinic
Rochester, Minnesota, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
Local Institution - 129
Mineola, New York, United States
David H Koch, Memorial Sloan Kettering Cancer Center
New York, New York, United States
New york cancer and blood specialists - Oncology
Port Jefferson Station, New York, United States
New york cancer and blood specialists - Oncology
Port Jefferson Station, New York, United States
University of North Carolina - Gastroenterology and Hepatology
Chapel Hill, North Carolina, United States
University of North Carolina
Chapel Hill, North Carolina, United States
Vanderbilt - Ingram Cancer Center
Nashville, Tennessee, United States
Ut Southwestern
Dallas, Texas, United States
Texas Oncology - DFW
Fort Worth, Texas, United States
MDACC
Houston, Texas, United States
South Texas Accelerated Research Therapeutics
San Antonio, Texas, United States
Texas Oncology, P.A. - Oncology
Tyler, Texas, United States
Virginia Cancer Specialists, PC
Fairfax, Virginia, United States
Local Institution - 134
Seattle, Washington, United States
Local Institution - 108
Milwaukee, Wisconsin, United States